Funding Opportunity PAR-21-217 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to diversify the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This initiative will emphasize the development of skills in data science and drug discovery, and their application to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). It will support research training of promising postdoctoral candidates from diverse backgrounds to help them gain critical translational skills in data science and drug discovery. The long-term goal of this program is to develop a diverse translational workforce that can effectively participate in and/or lead a team-science, precision medicine approach to AD/ADRD treatment, prevention, early detection, and disease management and care.

Funding Opportunity PAR-21-220 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to diversify the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This initiative will emphasize the development of skills in data science and drug discovery, and their application to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). This initiative will support early career, independent investigators from diverse backgrounds to gain critical translational skills in data science and drug discovery. The long-term goal of this program is to develop a diverse translational workforce that can effectively participate in and/or lead a team-science, precision medicine approach to AD/ADRD treatment, prevention, early detection, and disease management and care.

Notice NOT-MD-21-023 from the NIH Guide for Grants and Contracts

Notice NOT-OH-21-010 from the NIH Guide for Grants and Contracts

Notice NOT-GM-21-047 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-295 from the NIH Guide for Grants and Contracts

Notice NOT-TR-21-029 from the NIH Guide for Grants and Contracts

£40,000 - £55,000 plus bonus and benefits, including share options: Singular Talent: Want to find new drug targets in genetic data? Here's one for you.... Oxford, Oxfordshire (GB)

Notice NOT-MD-21-020 from the NIH Guide for Grants and Contracts

Our Experimental Error columnist offers his version of the new statement some employers are inviting

Notice NOT-OH-21-009 from the NIH Guide for Grants and Contracts

Notice NOT-DK-21-021 from the NIH Guide for Grants and Contracts

For this postdoc, caring colleagues and firm personal priorities were key

Skilled in the use of bioinformatics tools for antibody repertoire sequence and structure analyses. Present research findings to project teams and governance…
From Arrowhead Pharmaceuticals - Wed, 26 May 2021 23:41:02 GMT - View all Madison, WI jobs

This individual will be responsible for working with project personnel to implement bioinformatics and statistical methods for a myriad of project types; the…
From University of Wisconsin–Madison - Wed, 26 May 2021 18:57:22 GMT - View all Madison, WI jobs

Funding Opportunity RFA-HL-22-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of of highly trained investigators from diverse backgrounds , including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from Institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (see RFA-HL-22-010).

Notice NOT-NS-21-065 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-136 from the NIH Guide for Grants and Contracts

Notice NOT-DA-21-058 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-21-232 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative multidisciplinary and multi-level research designed to develop and/or test interventions to optimize care of persons with Type 2 diabetes from populations with health/health care disparities concordant with evidence-based guidelines. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations. Proposed projects would be expected to develop and/or test patient-centered strategies, which in addition to optimal glycemic control, would aim at completing other recommended guidelines (e.g., annual eye/foot and urine albumin exam, optimal blood pressure control, intake of ACEIs or ARBs/statin/aspirin and influenza/pneumonia vaccines).